Agenus/AGEN

$0.66

-1.32%
-
1D1W1MYTD1YMAX

About Agenus

Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. The Company is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company’s I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company’s antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.

Ticker

AGEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Garo Armen

Employees

533

Headquarters

Lexington, United States

Agenus Metrics

BasicAdvanced
$255.6M
Market cap
-
P/E ratio
-$0.81
EPS
1.27
Beta
-
Dividend rate

What the Analysts think about Agenus

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
884.85% upside
High $8.00
Low $6.00
$0.66
Current price
$6.50
Average price target

Agenus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-255.96% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$24.3M
-3.57%
Net income
$-62.2M
-9.86%
Profit margin
-255.96%
-6.52%

Agenus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.67%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.24
-$0.22
-$0.20
-$0.16
-
Expected
-$0.22
-$0.21
-$0.20
-$0.19
-$0.05
Surprise
9.92%
4.76%
0.84%
-16.67%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Agenus stock

Buy or sell Agenus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing